NEW YORK (360Dx) – Avant Diagnostics on Wednesday said it has acquired an exclusive option to license Genetic Health Solution's patient-delivery technology platform.
Avant said it plans to use the platform to develop a personalized cancer patient management program that will combine blood biomarker monitoring and drug side effect profiles to help reduce negative drug side effects in cancer patients.
Avant added that it is "evaluating an initial… launch in breast cancer" for its Theralink product, which uses measurements of patient protein phosphorylation levels to enable more effective targeting of cancer therapies. Avant acquired the Theralink portfolio when it acquired Theranostics Health as part of its 2016 merger with Amarantus Diagnostics.
Theranostics launched a 14-analyte version of Theralink for guiding therapy in breast cancer in 2013 and a 24-analyte version of that test in 2015. However, neither saw significant commercial uptake.